US Broker Ratings

Humacyte, Inc. (HUMA) Stock Analysis: Unveiling a Staggering 891% Potential Upside

In the ever-evolving landscape of biotechnology, Humacyte, Inc. (NASDAQ: HUMA) stands out with its pioneering approach to bioengineered human tissues. Based in Durham, North Carolina, this innovative biotechnology firm is..

Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring a Potential 663.89% Upside with Innovative CNS Treatments

Anavex Life Sciences Corp. (NASDAQ: AVXL) has been capturing attention within the healthcare and biotechnology sectors, primarily due to its innovative approach to treating central nervous system (CNS) disorders. With..

Xencor, Inc. (XNCR) Stock Analysis: A Healthcare Gem with 130% Upside Potential

Xencor, Inc. (XNCR) stands out in the biotechnology sector with promising potential for investors seeking opportunities in healthcare innovations. As a clinical-stage biopharmaceutical company, Xencor focuses on developing engineered antibodies..

MBX Biosciences, Inc. (MBX)

⚠️ No article content returned.

..

COMPASS Pathways Plc (CMPS) Stock Analysis: Exploring a Potential 285% Upside in Mental Health Innovations

COMPASS Pathways Plc (CMPS), a pioneering biotechnology firm based in the United Kingdom, is capturing the attention of investors with its innovative approach to mental health treatment. Specializing in psilocybin..

Bioventus Inc. (BVS) Stock Analysis: A Medical Device Specialist with 61.99% Potential Upside

Bioventus Inc. (NASDAQ: BVS), a healthcare company specializing in medical devices, has emerged as a compelling prospect for investors seeking growth in the medical technology sector. With a robust product..

Verastem, Inc. (VSTM) Stock Analysis: Exploring the 219% Upside Potential for This Biotech Innovator

Verastem, Inc. (NASDAQ: VSTM), a development-stage biopharmaceutical company focused on cancer treatment, is drawing considerable attention from the investment community. With a market capitalization of approximately $464.65 million, Verastem is..

Cullinan Therapeutics, Inc. (CGEM) Stock Analysis: Exploring 129% Potential Upside in the Biotech Sector

Investors with a keen eye on the healthcare sector might find Cullinan Therapeutics, Inc. (NASDAQ: CGEM) an intriguing prospect. This clinical-stage biopharmaceutical company, specializing in therapies for autoimmune diseases and..

Organogenesis Holdings Inc. (ORGO) Stock Analysis: Is the 230% Upside Worth the Investment Risk?

Organogenesis Holdings Inc. (NASDAQ: ORGO), a key player in the regenerative medicine sector, presents a compelling opportunity for investors seeking substantial upside potential. With a market capitalization of $311.31 million,..

Arbutus Biopharma Corporation (ABUS) Stock Analysis: Exploring a 26.60% Potential Upside in the Biotechnology Sector

Arbutus Biopharma Corporation (NASDAQ: ABUS) stands out in the biotechnology industry with a notable potential upside of 26.60% according to analyst ratings. As a clinical-stage biopharmaceutical company, Arbutus is making..

Upstream Bio, Inc. (UPB) Stock Analysis: Exploring a 388.84% Potential Upside Amidst Strong Buy Ratings

Investors seeking high-growth opportunities in the biotechnology sector might want to closely examine Upstream Bio, Inc. (NASDAQ: UPB). The company, which is making strides in developing treatments for inflammatory diseases,..

Cel-Sci Corporation (CVM) Stock Analysis: Exploring a 620% Potential Upside

Cel-Sci Corporation (NASDAQ: CVM), a clinical-stage biotechnology firm, is a compelling entity for investors seeking high-reward opportunities in the volatile biotech sector. The company, headquartered in Vienna, Virginia, has been..

MeiraGTx Holdings plc (MGTX) Stock Analysis: Unpacking a Potential 251.93% Upside in the Biotech Sector

MeiraGTx Holdings plc (NASDAQ: MGTX) is capturing investor attention with a potential upside of 251.93%, making it a tantalizing prospect in the biotechnology sector. This New York-based clinical-stage genetics medicines..

Embecta Corp. (EMBC) Stock Analysis: Exploring the 87.90% Potential Upside for Savvy Investors

As investors seek promising opportunities in the healthcare sector, Embecta Corp. (NASDAQ: EMBC) stands out with a compelling potential upside of 87.90%. Embecta, a New Jersey-based medical device company, has..

Orthofix Medical Inc. (OFIX): Investor Outlook Reveals 46% Potential Upside Amidst Undervalued Metrics

Orthofix Medical Inc. (NASDAQ: OFIX), a notable player in the healthcare sector, specifically within the medical devices industry, is drawing attention with a compelling potential upside of 46.31%. This analysis..

AMN Healthcare Services Inc (AMN) Stock Analysis: Unlocking 13.45% Potential Upside in the Healthcare Staffing Sector

AMN Healthcare Services Inc (NASDAQ: AMN) is a compelling player in the healthcare sector, specifically within the medical care facilities industry. Headquartered in Dallas, Texas, AMN is renowned for its..

ArriVent BioPharma, Inc. (AVBP) Stock Analysis: A Biotech Contender with 88.51% Potential Upside

ArriVent BioPharma, Inc. (AVBP), a clinical-stage biopharmaceutical company from Newtown Square, Pennsylvania, is carving a niche in the biotechnology sector with its innovative approach to cancer treatment. Specializing in the..

Valneva SE (VALN) Stock Analysis: Unpacking a 111.63% Potential Upside in the Biotech Sector

Valneva SE (NASDAQ: VALN), a French biotechnology company specializing in vaccine development, is making waves in the healthcare sector with a tantalizing potential upside of 111.63%. As of the latest..

Eton Pharmaceuticals, Inc. (ETON) Stock Analysis: A 67.73% Potential Upside Beckons Investors in Rare Disease Therapeutics

Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a niche player in the healthcare sector, is capturing the attention of investors with its robust portfolio of treatments targeting rare diseases. Based in Deer..

Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Uncovering a 216.55% Potential Upside in Healthcare

Investors searching for dynamic opportunities in the healthcare sector may find Akebia Therapeutics, Inc. (NASDAQ: AKBA) an intriguing candidate. With a market capitalization of $372.35 million and a focus on..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds